Biopharmaceutical and Biomedicine Market, by Product Type (Biopharmaceutical, Nano medicine, Gene Therapy, Bioinformatics, and Molecular Enzymes & Kits Market), and by Region - Global Industry Insights, and Forecast to 2025

  • Published On : Apr 2018 |
  • Pages : 285 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Biopharmaceutical and Biomedicine Market - Insights

Biopharmaceuticals are drugs that are partially or fully manufactured, or extracted from biological sources. Biopharmaceuticals contain variety of products such as monoclonal antibodies, vaccines, recombinant human insulin, human growth hormone, erythropoietin, interferon, colony stimulating factor, and blood factors. Currently, biopharmaceuticals accounts for over one-fifth of pharmaceutical market, and this percentage share of biopharmaceutical is expected to increase, owing to its advantage compared to totally synthesize pharmaceutical drugs. Fewer side effects, high effectiveness and potent action, and ability to cure the disease rather than treat are some of the major advantages of these drugs.

Continuous launch, approvals, and robust pipeline of biopharmaceutical products is expected to drive growth of the market 

In the recent past, regulatory bodies in key regions such as U.S. and Europe have approved a number of biopharmaceutical products, which have been subsequently launched in the market. For instance in 2017, Johnson & Johnson received U.S. FDA approval for its new immunology product—Tremfya (Guselkumab)—used for the treatment of moderate to severe plaque psoriasis. In 2017, Sanofi S.A. received U.S. FDA approval for its new Admelog, a rapid-acting insulin, indicated for the management of blood sugar levels at mealtime. In 2017, U.S. FDA approved GlaxoSmithKline Plc.’s New Shingrix, a shingles vaccine. FDA approved this vaccine to be used by people aged 50 years and above as an immunization against the painful condition caused by latent varicella infection. In 2017, Spark Therapeutics, Inc. received FDA approval for its LUXTURNA (voretigene neparvovec-rzyl). LUXTURNA is first gene therapy and pharmacologic treatment for an inherited retinal disease (IRD), and the first approved adeno-associated virus (AAV) vector gene therapy in the U.S. In 2017, HumanZyme Inc. launched its new HumanKine Interferon beta (IFN beta) expressed from HEK293 cells. IFN beta is an interferon of type I family, which activates Th1-type innate immune responses against viral and bacterial infection. In 2016, Novo Nordisk A/S launched its new next-generation once-daily basal insulin Tresiba (insulin degludec) in the U.S. market and in 2017, Nordisk A/S received China Food and Drug Administration (CFDA) approval to market its Tresiba (insulin degludec) in China. Such frequent launches and approvals of novel products is expected to drive growth of the market in the near future.

The global biopharmaceutical and biomedicine market was valued at US$ 358.4 Bn in 2016 and is expected to witness a CAGR of 9.4% over the forecast period (2017–2025).

Figure 1. Global Biopharmaceutical and Biomedicine Market Share (%), By Application, 2017 & 2025

biopharmaceutical and biomedicine market

Source: Coherent Market Insights Analysis (2017)

Increasing strategic acquisitions and collaboration by key players is expected to drive market growth in the near future

Players in the market are focusing on strategic collaborations, in order to increase their product offerings. In February 2018, LGC Limited— U.K.-based Company acquired Lucigen Corporation, a U.S.-based developer, and manufacturer of molecular biology enzymes, reagents and kits. Through this strategic acquisition, LGC Limited expanded its portfolio with the Lucigen’s extensive portfolio of NGS kits, enzymes, competent cells, and cloning systems. In February 2018, Servier Laboratories and ImmunoQure AG entered into a strategic collaboration for development of a therapeutic autoantibody neutralizing interferon- a. In March 2018, Wuxi Biologics Co. Ltd. collaborated with Adagene Inc., for the discovery and development of novel antibody therapeutics. In 2017, Omicia, Inc., acquired a bioinformatics startup Spiral Genetics at an undisclosed amount. Through this acquisition of Spiral’s advanced tools, Omicia, Inc., expanded its bioinformatics tools portfolio and strengthened its position in the global market.

Moreover, increasing funding and investments to support the development and research of new biopharmaceutical is also expected to drive the market growth. For instance in 2017, Indian government launched a National Biopharmaceutical Mission. As per the program, the government has invested US $250 Mn that includes a US$ 125 Mn loan from the World Bank to promote development of biological drugs in India. In 2017, The University of Liverpool and the Johns Hopkins University School of Medicine (JHUSM) collaborated for the development of new nanomedicine approaches for HIV therapy, and received an award of US$ 3 million from National Institutes of Health (NIH) to generate new technologies and continue research and development.

Cost of biopharmaceutical and biomedicine products are quite high as these need research and development process, and its manufacturing is very complex process, which needs highly skilled scientists. Such expensive biopharmaceutical products are not affordable to organizations in emerging economies such as India, China, and Africa. High cost of biopharmaceutical and biomedicine is a major factor hindering its adoption. For instance, in India a vial of Avastin, a monoclonal antibody, costs between US$ 372.65 to US$ 402.46. High cost medicine is not affordable to everyone, hence, it is a major restraining factor for the market growth. Cost of gene therapy such as Kymriah is very high. Kymriah is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia. The cost of Novartis AG’s cancer therapy Kymriah is about US$ 475,000.

Key players operating in the global biopharmaceutical and biomedicine market include Amgen Inc., F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol - Myers Squibb, NanoString Technologies, Inc., Qiagen N.V., Celgene Corporation, and Affimed N.V.

Biopharmaceuticals has emerged as one of the key segments with immense growth potential in the healthcare sector. Rising demand for effective treatment and rise in per capita healthcare expenditure has led to double digit revenue growth for industry players in the recent past. The industry offers lucrative growth opportunities, since most of these products still have low penetration rate. The market is expected to gain further traction, with evolving treatment archetypes and rapid technological innovation such as cell therapy and regenerative medicines.

Market Dynamics

Launches and approvals of novel biopharmaceutical and biomedicine products is expected to drastically drive growth of global biopharmaceutical and biomedicine market in the near future. For instance, in 2016, Sanofi S.A. received U.S. FDA approval for its Adlyxin ((lixisenatide) injection. Adlyxin is indicated to improve blood sugar levels among adults suffering from type 2 diabetes. In 2016, Johnson & Johnson received U.S. FDA approval for its Stelara (Ustekinumab), indicated for the treatment of adults suffering from moderately to severely active crohn’s disease. In 2016, CSL Behring received U.S. FDA approval for its IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein. IDELVION is indicated for the treatment of Hemophilia B among children and adults. In 2017, Nanostring Technologies, Inc. launched nCounter platform advances as well as new panels expanding the company’s presence in immuno-oncology and 3D biology research. In 2015, Celltrion Healthcare Co., Ltd. launched its Remsima (infliximab), a biosimilar monoclonal antibody (mAb) in Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden, and the UK. Furthermore, increasing collaborations and acquisitions by major key players in market is also expected to create lucrative environment for growth of market. For instance, in 2016, Biocon Ltd., wholly owned subsidiary of Biocon SA, collaborated with Laboratorios PiSA S.A. de C.V—a Mexico-based company—for the co-development and commercialization of generic recombinant human insulin (rh-insulin) in the U.S. market. In 2016, AbbVie Inc. acquired all rights from Boehringer Ingelheim (BI) for Risankizumab (BI 655066). Risankizumab is an anti-IL-23 monoclonal biologic antibody for psoriasis. Company is also evaluating the product for other indications such as Crohn’s disease, asthma, and psoriatic arthritis. Currently, it is in clinical phase 3.

Key features of the study:

  • This report provides in-depth analysis of biopharmaceutical and biomedicine market and provides market size (US$ Billion) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global biopharmaceutical and biomedicine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Amgen Inc., F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol - Myers Squibb, NanoString Technologies, Inc., Qiagen N.V., Celgene Corporation, and Affimed N.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global biopharmaceutical and biomedicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the biopharmaceutical and biomedicine market

Detailed Segmentation:

  • Global Biopharmaceutical and Biomedicine Market, By Product Type :
    • Biopharmaceutical
      • Monoclonal Antibodies Market
      • Vaccines
      • Recombinant Human Insulin
      • Human Growth Hormone
      • Erythropoietin
      • Interferon
      • Colony Stimulating Factor
      • Blood Factors
      • Fusion Protein
      • Others
    • Nanomedicine
    • Cell & Gene Therapy
    • Bioinformatics
    • Molecular Enzymes & Kits Market
  • Global Biopharmaceutical and Biomedicine Market, By Application:
    • Therapeutics
    • Diagnostics
    • Research and Development
  • Global Biopharmaceutical and Biomedicine Market, By Geography:
    • North America
      • By Product Type :
        • Biopharmaceutical
          • Monoclonal Antibodies Market
          • Vaccines
          • Recombinant Human Insulin
          • Human Growth Hormone
          • Erythropoietin
          • Interferon
          • Colony Stimulating Factor
          • Blood Factors
          • Fusion Protein
          • Others
        • Nanomedicine
        • Cell & Gene Therapy
        • Bioinformatics
        • Molecular Enzymes & Kits Market
      • By Application:
        • Therapeutics
        • Diagnostics
        • Research and Development
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Product Type :
        • Biopharmaceutical
          • Monoclonal Antibodies Market
          • Vaccines
          • Recombinant Human Insulin
          • Human Growth Hormone
          • Erythropoietin
          • Interferon
          • Colony Stimulating Factor
          • Blood Factors
          • Fusion Protein
          • Others
        • Nanomedicine
        • Cell & Gene Therapy
        • Bioinformatics
        • Molecular Enzymes & Kits Market
      • By Application:
        • Therapeutics
        • Diagnostics
        • Research and Development
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type :
        • Biopharmaceutical
          • Monoclonal Antibodies Market
          • Vaccines
          • Recombinant Human Insulin
          • Human Growth Hormone
          • Erythropoietin
          • Interferon
          • Colony Stimulating Factor
          • Blood Factors
          • Fusion Protein
          • Others
        • Nanomedicine
        • Cell & Gene Therapy
        • Bioinformatics
        • Molecular Enzymes & Kits Market
      • By Application:
        • Therapeutics
        • Diagnostics
        • Research and Development
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Product Type :
        • Biopharmaceutical
          • Monoclonal Antibodies Market
          • Vaccines
          • Recombinant Human Insulin
          • Human Growth Hormone
          • Erythropoietin
          • Interferon
          • Colony Stimulating Factor
          • Blood Factors
          • Fusion Protein
        • Others
      • By Application:
        • Therapeutics
        • Diagnostics
        • Research and Development
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Product Type :
        • Biopharmaceutical
          • Monoclonal Antibodies Market
          • Vaccines
          • Recombinant Human Insulin
          • Human Growth Hormone
          • Erythropoietin
          • Interferon
          • Colony Stimulating Factor
          • Blood Factors
          • Fusion Protein
        • Others
      • By Application:
        • Therapeutics
        • Diagnostics
        • Research and Development
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type :
        • Biopharmaceutical
          • Monoclonal Antibodies Market
          • Vaccines
          • Recombinant Human Insulin
          • Human Growth Hormone
          • Erythropoietin
          • Interferon
          • Colony Stimulating Factor
          • Blood Factors
          • Fusion Protein
        • Others
      • By Application:
        • Therapeutics
        • Diagnostics
        • Research and Development
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Amgen Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments
      • Key Strategies
    • Hoffmann-La Roche AG
    • Novartis AG
    • Johnson & Johnson
    • Pfizer, Inc.
    • Sanofi S.A.
    • Eli Lilly and Company
    • AbbVie Inc.
    • Novo Nordisk A/S
    • Bristol - Myers Squibb
    • NanoString Technologies, Inc.
    • Qiagen N.V.
    • Celgene Corporation
    • Affimed N.V.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • PEST Analysis
    • Pipeline Analysis
    • Product Approval
    • Product Launch
    • Collaboration-Acquisition
    • Porter’s Five Forces Analysis
  4. Global Biopharmaceutical and Biomedicine Market, By Product Type, 2015–2025 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Biopharmaceutical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Bn)
      • Segment Trends
        • Monoclonal Antibodies Market
        • Vaccines
        • Recombinant Human Insulin
        • Human Growth Hormone
        • Erythropoietin
        • Interferon
        • Colony Stimulating Factor
        • Blood Factors
        • Fusion Protein
        • Others
    • Nanomedicine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Bn)
    • Cell & Gene Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Bn)
    • Bioinformatics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Bn)
    • Molecular Enzymes & Kits Market
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Bn)
  5. Global Biopharmaceutical and Biomedicine Market, By Application, 2015–2025 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2016–2025
      • Segment Trends
    • Therapeutics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Bn)
    • Diagnostics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Bn)
    • Research and Development
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2015–2025, (US$ Bn)
  6. Global Biopharmaceutical and Biomedicine Market, By Region, 2015–2025 (US$ Bn)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2016–2025
    • North America
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Bn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Bn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Bn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Bn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Product Type, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Application, 2015–2025 (US$ Bn)
      • Market Size and Forecast, By Country, 2015–2025 (US$ Bn)
        • GCC
        • Israel
        • Rest of Middle East
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol - Myers Squibb
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • NanoString Technologies, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Qiagen N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Celgene Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Affimed N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 45 market data tables and 42 figures on “Biopharmaceutical and Biomedicine Market - Global forecast to 2025”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.